Finally, a recent study by [108] was the first to trial low-dose IL-2 in combination with adoptive Treg therapy to treat T1D, however, this too failed to reach its secondary outcome measure of a reduction in c-peptide decline. The gene discussed is IL2; the disease is type 1 diabetes mellitus.